Univariate and multivariate Cox regression analyses of AML of the Epo-G (n = 123) and the selected IPSS/IMRAW (n = 334) cohorts together
. | Total no. . | No. AML . | Unadjusted odds . | 95% CI . | P . | Adjusted odds . | 95% CI . | P . |
|---|---|---|---|---|---|---|---|---|
| Cohort | ||||||||
| IPSS/IMRAW | 334 | 57 | Ref | — | — | Ref | — | — |
| Epo-G | 123 | 33 | 1.3 | 0.9-2.0 | .22 | 1.3 | 0.7-2.2 | .40 |
| No. of cytopenias | ||||||||
| 0 or 1 | 196 | 26 | Ref | — | — | Ref | — | — |
| 2 or 3 | 261 | 64 | 2.8 | 1.8-4.4 | <.001 | 2.0 | 1.2-3.3 | .004 |
| Karyotype* | ||||||||
| Good | 300 | 43 | Ref | — | — | Ref | — | — |
| Intermediate | 68 | 17 | 2.1 | 1.2-3.6 | .01 | 2.0 | 1.1-3.5 | .02 |
| Poor | 81 | 27 | 4.2 | 2.6-6.9 | <.001 | 4.0 | 2.4-6.7 | <.001 |
| Unknown | 8 | 3 | 3.5 | 1.1-11.2 | .04 | 1.4 | 0.4-4.8 | .63 |
| BM blasts | ||||||||
| Less than 5% | 277 | 32 | Ref | — | — | Ref | — | — |
| 5% to 10% | 121 | 37 | 3.8 | 2.4-6.1 | <.001 | 2.8 | 1.7-4.7 | <.001 |
| 11% to 20% | 59 | 21 | 8.1 | 4.6-14.4 | <.001 | 6.3 | 3.3-12.0 | <.001 |
| Age | ||||||||
| 16 to 45 y | 19 | 5 | Ref | — | — | Ref | — | — |
| 46 to 55 y | 50 | 14 | 1.0 | 0.4-2.9 | .96 | 1.6 | 0.5-4.5 | .40 |
| 56 to 65 y | 95 | 22 | 0.9 | 0.3-2.4 | .83 | 0.9 | 0.3-2.5 | .86 |
| 66 to 75 y | 133 | 30 | 1.0 | 0.4-2.6 | .99 | 1.2 | 0.4-3.2 | .73 |
| 76 to 85 y | 135 | 17 | 0.6 | 0.2-1.6 | .32 | 0.8 | 0.3-2.2 | .66 |
| More than 85 y | 25 | 2 | 0.4 | 0.1-2.3 | .33 | 0.4 | 0.1-2.1 | .27 |
| Sex | ||||||||
| Male | 255 | 55 | Ref | — | — | Ref | — | — |
| Female | 202 | 35 | 0.7 | 0.5-1.1 | .11 | 0.8 | 0.5-1.3 | .42 |
| Study | ||||||||
| Non-Epo-G study III | 405 | 82 | Ref | — | — | Ref | — | — |
| Epo-G study III | 52 | 8 | 0.7 | 0.3-1.4 | .27 | 0.8 | 0.3-1.8 | .51 |
. | Total no. . | No. AML . | Unadjusted odds . | 95% CI . | P . | Adjusted odds . | 95% CI . | P . |
|---|---|---|---|---|---|---|---|---|
| Cohort | ||||||||
| IPSS/IMRAW | 334 | 57 | Ref | — | — | Ref | — | — |
| Epo-G | 123 | 33 | 1.3 | 0.9-2.0 | .22 | 1.3 | 0.7-2.2 | .40 |
| No. of cytopenias | ||||||||
| 0 or 1 | 196 | 26 | Ref | — | — | Ref | — | — |
| 2 or 3 | 261 | 64 | 2.8 | 1.8-4.4 | <.001 | 2.0 | 1.2-3.3 | .004 |
| Karyotype* | ||||||||
| Good | 300 | 43 | Ref | — | — | Ref | — | — |
| Intermediate | 68 | 17 | 2.1 | 1.2-3.6 | .01 | 2.0 | 1.1-3.5 | .02 |
| Poor | 81 | 27 | 4.2 | 2.6-6.9 | <.001 | 4.0 | 2.4-6.7 | <.001 |
| Unknown | 8 | 3 | 3.5 | 1.1-11.2 | .04 | 1.4 | 0.4-4.8 | .63 |
| BM blasts | ||||||||
| Less than 5% | 277 | 32 | Ref | — | — | Ref | — | — |
| 5% to 10% | 121 | 37 | 3.8 | 2.4-6.1 | <.001 | 2.8 | 1.7-4.7 | <.001 |
| 11% to 20% | 59 | 21 | 8.1 | 4.6-14.4 | <.001 | 6.3 | 3.3-12.0 | <.001 |
| Age | ||||||||
| 16 to 45 y | 19 | 5 | Ref | — | — | Ref | — | — |
| 46 to 55 y | 50 | 14 | 1.0 | 0.4-2.9 | .96 | 1.6 | 0.5-4.5 | .40 |
| 56 to 65 y | 95 | 22 | 0.9 | 0.3-2.4 | .83 | 0.9 | 0.3-2.5 | .86 |
| 66 to 75 y | 133 | 30 | 1.0 | 0.4-2.6 | .99 | 1.2 | 0.4-3.2 | .73 |
| 76 to 85 y | 135 | 17 | 0.6 | 0.2-1.6 | .32 | 0.8 | 0.3-2.2 | .66 |
| More than 85 y | 25 | 2 | 0.4 | 0.1-2.3 | .33 | 0.4 | 0.1-2.1 | .27 |
| Sex | ||||||||
| Male | 255 | 55 | Ref | — | — | Ref | — | — |
| Female | 202 | 35 | 0.7 | 0.5-1.1 | .11 | 0.8 | 0.5-1.3 | .42 |
| Study | ||||||||
| Non-Epo-G study III | 405 | 82 | Ref | — | — | Ref | — | — |
| Epo-G study III | 52 | 8 | 0.7 | 0.3-1.4 | .27 | 0.8 | 0.3-1.8 | .51 |
Ref indicates reference category.
Karyotype categories good, intermediate, and poor according to the IPSS.